Related Experiment Videos
Pneumonia due to unusual organisms in children
1Department of Pediatrics, Sir Ganga Ram Hospital, New Delhi.
Abstract:
Generally antimicrobials for treatment of pneumonia are chosen to target the usual bacterial etiological agents. Such regimens are unable to cure patients of pneumonia caused by 'unusual organisms' mycoplasma, chlamydia, Pneumocystis carinii and Legionella pneumophilus). Thus, there is a need to anticipate their presence in appropriate cases and to plan the initial antimicrobial therapy accordingly. Studies in Europe as well as India have shown that such infections form a fairly substantial percentage of community acquired pneumonia in children. Mycoplasma pneumoniae and Chlamydia pneumoniae are common in school age children while Chlamydia trachomatis occurs in early infancy. Pneumocystis carinii is an important pathogen in immunocompromised children. Routine laboratory tests and radiological features are not specific enough to give accurate diagnosis of these infections for which one has to depend on sophisticated culture techniques, immunological tests for the antigens or antibodies and polymerase chain reaction. Mycoplasma, chlamydia and legionella infections respond to macrolide antibiotics and for pneumocystis infections, trimethoprim-sulfamethaxozole or pentamidine is the drug of choice. Overall prognosis with appropriate treatment is good except for P. carinii infection in immunocompromised host which carries a high mortality and recurrence rate.
Insights
Antimicrobials for typical pneumonia fail against unusual pathogens like Mycoplasma and Chlamydia. Early diagnosis and targeted therapy are crucial for better outcomes in pediatric community-acquired pneumonia.
Area of Science:
- Pediatric infectious diseases
- Respiratory medicine
- Microbiology
Background:
- Community-acquired pneumonia (CAP) in children is often treated with antimicrobials targeting common bacterial agents.
- Standard treatment regimens may be ineffective against atypical pathogens such as Mycoplasma, Chlamydia, Pneumocystis carinii, and Legionella pneumophilus.
- These atypical infections constitute a significant proportion of pediatric CAP in various regions.
Purpose of the Study:
- To highlight the importance of considering and anticipating atypical organisms in pediatric pneumonia.
- To emphasize the need for appropriate initial antimicrobial therapy planning for these infections.
- To discuss diagnostic challenges and treatment strategies for atypical pneumonia in children.
Main Methods:
- Review of existing studies on the prevalence of atypical pathogens in pediatric CAP.
- Discussion of diagnostic methods, including advanced techniques like PCR and immunological tests.
- Analysis of treatment responses to specific antimicrobial agents.
Main Results:
- Mycoplasma pneumoniae and Chlamydia pneumoniae are prevalent in school-aged children, while Chlamydia trachomatis affects infants.
- Pneumocystis carinii is a significant pathogen in immunocompromised children.
- Atypical infections require specialized diagnostic approaches beyond routine tests and imaging.
Conclusions:
- Effective treatment for Mycoplasma, Chlamydia, and Legionella relies on macrolide antibiotics.
- Trimethoprim-sulfamethoxazole or pentamidine are the preferred treatments for Pneumocystis infections.
- While prognosis is generally good with appropriate therapy, P. carinii in immunocompromised hosts carries a high mortality risk.